{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:48:29Z","timestamp":1787496509911,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cultivation Discipline of Chongqing Hospital of Traditional Chinese Medicine"},{"name":"National Advantageous Specialty of Traditional Chinese Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Endothelin A receptor activation is a key driver of proteinuria, inflammation and fibrosis in IgAN. This systematic review and meta-analysis aimed to comprehensively evaluate the efficacy and safety of endothelin A receptor antagonists (EARAs) in IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science and Cochrane Library were searched from inception to 31 October 2024. All randomized controlled trials were identified according to the inclusion criteria. Data were analyzed by RevMan 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four high-quality studies were included, comprising 1346 IgAN patients. Compared with the control group, EARAs group achieved a greater reduction in urine protein\u2013creatinine ratio (UPCR) [mean difference (MD) \u201331.89, 95% confidence interval (CI) \u201337.50 to \u201326.28], systolic blood pressure (BP) (MD \u20132.78, 95% CI \u20134.11 to \u20131.44) and diastolic BP (MD \u20134.12, 95% CI \u20135.24 to \u20132.99), and a smaller reduction in estimated glomerular filtration rate (eGFR) (MD 4.10, 95% CI \u20130.76 to 8.96). However, the EARAs group had higher risk of anemia [odds ratio (OR) 2.38, 95% CI 1.54 to 3.69], cough (OR 2.27, 95% CI 1.24 to 4.15), dizziness (OR 2.37, 95% CI 1.51 to 3.71), hypotension (OR 2.39, 95% CI 1.56 to 3.67), fluid retention (OR 1.46, 95% CI 1.04 to 2.05) and acute kidney injury (OR 3.12, 95% CI 1.31 to 7.42).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EARAs can significantly reduce UPCR, lower both systolic and diastolic BP, and delay eGFR decline in IgAN patients. However, they may cause anemia, cough, dizziness, hypotension, fluid retention and acute kidney injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf066","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:19:50Z","timestamp":1740554390000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5158-876X","authenticated-orcid":false,"given":"Zhonghua","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixiong","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhie","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Chongqing Emergency Medical Center , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025040309382486800_bib1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"2025040309382486800_bib2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2025040309382486800_bib3","doi-asserted-by":"publisher","first-page":"1461879","DOI":"10.3389\/fmed.2024.1461879","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Barratt","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025040309382486800_bib4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2025040309382486800_bib5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040309382486800_bib6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ekir.2023.11.026","article-title":"Novel treatment paradigms: primary IgA nephropathy","volume":"9","author":"Selvaskandan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025040309382486800_bib7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/001c.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"2025040309382486800_bib8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2025040309382486800_bib9","doi-asserted-by":"publisher","first-page":"572754","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"2025040309382486800_bib10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000541576","article-title":"Off-label use of mycophenolate mofetil in immunoglobulin A nephropathy: a systematic review and meta-analysis","volume":"56","author":"Feng","year":"2024","journal-title":"Am J Nephrol"},{"key":"2025040309382486800_bib11","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.2174\/0113816128304327240620093048","article-title":"Treatment of patients with IgA nephropathy: evaluation of the safety and efficacy of mycophenolate mofetil","volume":"30","author":"Chen","year":"2024","journal-title":"Curr Pharm Des"},{"key":"2025040309382486800_bib12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025040309382486800_bib13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2025040309382486800_bib14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000188912","article-title":"Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy","volume":"72","author":"Nakamura","year":"1996","journal-title":"Nephron"},{"key":"2025040309382486800_bib15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2025040309382486800_bib16","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2025040309382486800_bib17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000538","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2025040309382486800_bib18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"2025040309382486800_bib19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025040309382486800_bib20","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2025040309382486800_bib21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040309382486800_bib22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025040309382486800_bib23","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","article-title":"Contemporary review of IgA nephropathy","volume":"15","author":"Filippone","year":"2024","journal-title":"Front Immunol"},{"key":"2025040309382486800_bib24","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/ndt\/gfae021","article-title":"Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy","volume":"39","author":"Nagasawa","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025040309382486800_bib25","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1016\/j.ekir.2021.03.396","article-title":"POS-378 selective ETA antagonist atrasentan, rapidly reduces albuminurla and downergulates intra-renal pro-inflammatory and pro-fibrotic transcriptional networks in the gddy mouse model of spontaneous IgA nephropathy","volume":"6","author":"King","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025040309382486800_bib26","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2025040309382486800_bib27","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2016.22.3-a.s3","article-title":"New therapeutic paradigms and guidelines in the management of pulmonary arterial hypertension","volume":"22","author":"Hill","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2025040309382486800_bib28","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","volume":"64","author":"Chin","year":"2024","journal-title":"Eur Respir J"},{"key":"2025040309382486800_bib29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ejhf.2830","article-title":"European society of cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the heart failure association of the European Society of Cardiology","volume":"25","author":"Aktaa","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025040309382486800_bib30","doi-asserted-by":"publisher","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2025040309382486800_bib31","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1111\/bph.16504","article-title":"The role of venous capacity in fluid retention with endothelin A antagonism: mathematical modelling of the RADAR trial","volume":"181","author":"Yu","year":"2024","journal-title":"Br J Pharmacol"},{"key":"2025040309382486800_bib32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2215\/CJN.07040713","article-title":"Predictors of congestive heart failure after treatment with an endothelin receptor antagonist","volume":"9","author":"Hoekman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040309382486800_bib33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jchf.2022.03.004","article-title":"Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure","volume":"10","author":"Smeijer","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025040309382486800_bib34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1177\/2047487315598709","article-title":"Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers","volume":"23","author":"Schievink","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2025040309382486800_bib35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"2025040309382486800_bib36","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1093\/ndt\/gfm364","article-title":"Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease","volume":"22","author":"Dhaun","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025040309382486800_bib37","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","article-title":"Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade","volume":"109","author":"Goddard","year":"2004","journal-title":"Circulation"},{"key":"2025040309382486800_bib38","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025040309382486800_bib39","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"2025040309382486800_bib40","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMc2401126","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"2025040309382486800_bib41","doi-asserted-by":"publisher","first-page":"e13750","DOI":"10.1111\/cts.13750","article-title":"Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist","volume":"17","author":"Liu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2025040309382486800_bib42","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf066\/62200574\/sfaf066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/3\/sfaf066\/62200574\/sfaf066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/3\/sfaf066\/62200574\/sfaf066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T06:13:51Z","timestamp":1743660831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf066\/8045599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf066","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,27]]},"article-number":"sfaf066"}}